TCT: Bivalirudin Cuts Bleeding in PCI
WASHINGTON (MedPage Today) -- A prolonged infusion of bivalirudin (AngioMax) around percutaneous coronary intervention reduced bleeding compared with heparin, with or without glycoprotein IIb/IIIa inhibition, a Chinese trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 15, 2014 Category: Cardiology Source Type: news
New Revascularization Guidelines Trim Back Bivalirudin, DAPTNew Revascularization Guidelines Trim Back Bivalirudin, DAPT
New European guidelines for PCI and CABG in stable CAD, NSTEMI, and STEMI were unveiled last week with some key changes from previous documents. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 11, 2014 Category: Cardiology Tags: Cardiology News Source Type: news
Bivalirudin versus heparin in patients planned for coronary stenting
(Brigham and Women's Hospital) Researchers from Brigham and Women's Hospital conducted an analysis of all of the previous trials to date to better define both the benefits and risks of the competing anticoagulants. They found that, compared with heparin-based regimens, bivalirudin-based regimens increased the risk of heart attack and stent thrombosis. Bivalirudin-based regimens decreased the risk of bleeding, but by how much depended on whether other blood thinners were used more with heparin than with bivalirudin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 15, 2014 Category: Global & Universal Source Type: news
Consistency of Signals in Bivalirudin/Heparin Meta-Analysis Consistency of Signals in Bivalirudin/Heparin Meta-Analysis
Authors of a new meta-analysis of bivalirudin vs heparin trials of PCI patients say their findings provide a cool second look at a debate that reached a new boiling point in HEAT-PPCI. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
Heparin in Stent Patients: New Love for an Old Friend (CME/CE)
(MedPage Today) -- Results of a meta-analysis of data from some 34,000 PCI patients suggest that Angiomax (bivalirudin) may not be the best choice for anticoagulation in stent patients, but an old, cheap drug -- heparin -- could be. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 14, 2014 Category: Geriatrics Source Type: news
PCI and ACS: Where Do Vorapaxar and Bivalirudin Fit In?PCI and ACS: Where Do Vorapaxar and Bivalirudin Fit In?
Drs. Pereira and Sandhu discuss contemporary therapy now that vorapaxar is approved. Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 30, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Choices, Choices: PCI Adjunctive PharmacotherapyChoices, Choices: PCI Adjunctive Pharmacotherapy
Drs. Mehran and Cuisset discuss key studies from EuroPCR and the role of bivalirudin in a post-EUROMAX, post-HEAT-PPCI world. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 10, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Heparin Beats Bivalirudin in Primary PCI (FREE)
By Larry Husten
Edited by David G. Fairchild, MD, MPH, and André Sofair, MD, MPH
Bivalirudin is associated with a higher rate of major adverse cardiac events than heparin in patients with myocardial infarction undergoing primary percutaneous coronary intervention, according to a Lancet study.Roughly 1800 patients undergoing primary … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 8, 2014 Category: Primary Care Source Type: news
Controversial Trial Finds No Benefit For Expensive Medicines Company Drug
Although there is broad consensus in the medical community that immediate stenting (primary PCI) is the best treatment for heart attack patients when it can be delivered promptly, there is no agreement about the best accompanying drug regimen, which usually entails a combination of antiplatelet and antithrombotic drugs. The role of one antithrombotic, bivalirudin (Angiomax, The Medicines Company) has been particularly uncertain because it is far more expensive than its alternative, unfractionated heparin. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 7, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
HEAT-PPCI in Print: 'It's Pretty Bloody Detailed'HEAT-PPCI in Print: 'It's Pretty Bloody Detailed'
The bivalirudin vs heparin trial that caused such a sensation earlier this year is now published in the Lancet and should put all questions to rest, the senior investigator says. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
REGULATE-PCI Paused; DSMB Reviews Allergic Reactions, SafetyREGULATE-PCI Paused; DSMB Reviews Allergic Reactions, Safety
The 13 200-patient phase 3 trial is testing a fully "controllable" antithrombotic system against bivalirudin in the setting of PCI for ACS. Over 3300 patients have been randomized to date. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 4, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
The Lancet: New trial suggests cheaper drugs for common heart attack procedure could improve outcomes and save health budgets millions
(The Lancet) A new study published in The Lancet compares outcomes for two drugs used to prevent blood clot formation during emergency heart attack treatment. The study suggests that use of one of the drugs, heparin, could result in improved outcomes (such as a reduced rate of repeat heart attacks), compared to the other drug tested, bivalirudin, which is in widespread use in high-income countries, and is around 400 times more expensive than heparin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 4, 2014 Category: Global & Universal Source Type: news
EUROMAX Data Put Heat on HEAT via New Bivalirudin AnalysisEUROMAX Data Put Heat on HEAT via New Bivalirudin Analysis
EuroMAX investigators delved back into their data to remove routine GP IIb/IIIa-inhibitor use from the equation and say bivalirudin still beats heparin in STEMI. But with answers come new questions. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 22, 2014 Category: Cardiology Tags: Cardiology News Source Type: news
Bivalirudin Bleeding? More from NAPLES III, BRAVE 4, BRIGHTBivalirudin Bleeding? More from NAPLES III, BRAVE 4, BRIGHT
HEAT-PPCI results earlier this week caught cardiologists off guard, as it went against other large bivalirudin trials. Two smaller ACC 2014 trials are now also gaining attention in the wake of HEAT. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 5, 2014 Category: Cardiology Tags: Cardiology News Source Type: news
BRAVE-4 and HEAT-PPCI: Bivalirudin Takes a HitBRAVE-4 and HEAT-PPCI: Bivalirudin Takes a Hit
Drs. Byrne, Shahzad, and Stables review 2 trials showing no bleeding advantage for bivalirudin when bailout GP IIb/IIIa was used in both study arms. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 3, 2014 Category: Cardiology Tags: Cardiology Roundtable Source Type: news
